CytomX Therapeutics公司研发的Varsetatug Masetecan（EpCAM Probody®抗体偶联药物）最新临床数据持续呈现积极信号，这项创新疗法或将为晚期结直肠癌患者提供新的治疗选择。数据显示，该药物在经多轮治疗的患者群体中仍能保持显著抗肿瘤活性，其独特的作用机制有望突破现有后线治疗瓶颈。
作为靶向EpCAM的精准疗法，该ADC药物通过智能探针技术有效区分病变组织与健康细胞，在提升疗效的同时显著降低毒副作用。最新临床证据进一步验证了其耐受性与临床获益率的可持续性，为后续适应症拓展奠定基础。随着结直肠癌后线治疗需求日益迫切，该疗法的开发进展备受行业关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.